Figure 6.

Efficacy and tolerability of BRD9 inhibitor 2 in a xenograft model of human AML. Data for panels a–d was collected in the same in vivo experiment. (a) CIEA-NOG mice were injected intravenously with 10⁷ EOL-1 AML cells. Starting on day 5 after cell injection, mice were orally treated with vehicle (daily) or with 180 mg/kg 2 (qd5–17 and qd20–22). With the help of bioluminescence imaging, the tumor burden was assessed in each animal on days 5, 8, 11, 14, and 18 and calculated as median average radiance [p/s/cm²/sr]. One-sided decreasing Mann–Whitney tests were used to compare tumor volumes. (b) Bioluminescence imaging on day 18: (upper) vehicle control and (lower) 180 mg/kg 2. (c) Average body weight changes as a percentage of the initial weight. (d) Kaplan–Meier curve showing prolonged survival of animals treated with 180 mg/kg 2 (vehicle = black line; 180 mg/kg 2 = blue line). The p-value was calculated by Mann–Whitney test.